Why the study?
Severe tricuspid regurgitation carries significant morbidity and adverse prognosis, yet symptomatic disease remains undertreated despite emerging therapeutic modalities.
This review highlights the growing recognition of severe tricuspid regurgitation and summarizes emerging percutaneous therapies that show promise for transcatheter valve repair and replacement.
Tricuspid regurgitation (TR) is a relatively common finding. There has been growing recognition of the morbidity and adverse prognosis of severe TR, which affects 1.6 million people in the US. However, symptomatic TR remains undertreated despite emerging therapeutic modalities. In this review, the pathophysiological and epidemiological features of TR are examined and the diagnosis, natural history, and clinical presentation are discussed. An overview of TR therapy is provided, including medical and surgical treatments, as well as novel percutaneous approaches. The currently available studies on percutaneous therapy demonstrate promise for transcatheter valve repair and replacement with favourable clinical outcomes and short-term durability. However, further study is needed.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: